NR3C2 and diabetic kidney disease: Recently, renin-angiotensin system inhibitors, non-steroidal mineralocorticoid receptor antagonists, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists were proposed as the four pillars for treating DKD.